Home » Topics » Disease categories and therapies » Immune

Immune
RSS

Cell Therapeutics presents new inhibitors of IL-12 and IL-4 signaling for asthma, diabetes, etc.

Oct. 30, 2002

Cytovaxine phase I trial completes enrollment

Oct. 29, 2002

Celgene advances first JNK inhibitor into clinic

Oct. 23, 2002

Merckle claims novel compounds with cytokine-modulatory activity

Oct. 23, 2002

FluINsure challenge study cleared in U.K.

Oct. 18, 2002

Ras inhibitor FTS reduces autoantibodies in animal models of APS

Oct. 18, 2002

Anthrax vaccine advances to clinical testing at Walter Reed

Oct. 17, 2002

Enrollment completed in phase IIA kidney transplantation trial of ISA-247

Oct. 16, 2002

Ciclosporin-loaded microspheres assessed for efficacy and safety in corneal rejection model

Oct. 15, 2002

Timing of single doses of FK-506 important for limb allograft success

Oct. 14, 2002

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...
Pharma industry faces long haul to get return on investment from AI
BioWorld Science
Artificial intelligence tools are springing up at multiple points along drug discovery and development, but despite the hype, as yet there is minimal return on...